So far, so good. That may not be your immediate take away as you read the rest of the first page but I’m fairly content with how the first month of the year is unfolding. Yes, I think we may
January 29, 2018
SAN CARLOS, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the closing of an underwritten public offering of 15,000,000 shares of its common